Fatima Abdul Azeez,
- Student, Department of Biotechnology, Mar Athanasius College, Kothamangalam, kerela, India
Abstract document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_abs_114088’);});Edit Abstract & Keyword
Objective: Alpha-synuclein (α-Syn) aggregates are a common neurodegenerative disorder associated with Parkinson’s disease and Multiple System Atrophy (MSA). As a fruit that is extensively grown, grapes have several pharmacological advantages when it comes to reducing oxidative stress. Research has indicated that grape seed phytoconstituents have a major effect on α-Syn. The objective of this study is to inquire into the pharmacological characteristics and potential therapeutic applications of grape seed derivatives against the targeted protein, α-Syn. Methods: In order to assess their binding affinity with α-Syn, thirty distinct grape seed components and their phytoconstituents were chosen for this investigation. The PyRx virtual tool was employed for molecular docking processes, utilizing computational analysis based on the molecular structures of both phytocompounds and α-Syn. The protein structure was verified using a collection of tools, such as the PDBsum generator and BIOVIA Discovery Studio program. Furthermore, ADMET filters were used to evaluate the ligands pharmacologically. Result: The molecular docking studies indicated that thiamine, the ligand, had a low binding affinity for the protein α-Syn, which was the target. Conclusion: As thiamine has been shown to be a therapeutic agent against α-Syn in Parkinson’s disease research, it may be a good choice for MSA and can be utilised to lessen its effects. To validate these results, in vitro studies are still necessary.
Keywords: Multiple System Atrophy, alpha-synuclein, grapeseed, thiamine, ADMET analysis, Phytoconstituents, Ramachandran plot, Molecular docking.
[This article belongs to International Journal of Molecular Biotechnological Research (ijmbr)]
Fatima Abdul Azeez. Exploring the Therapeutic Potential of Grapeseed Phytoconstituent through Molecular Docking Analysis for Multiple System Atrophy Treatment. International Journal of Molecular Biotechnological Research. 2024; 02(02):-.
Fatima Abdul Azeez. Exploring the Therapeutic Potential of Grapeseed Phytoconstituent through Molecular Docking Analysis for Multiple System Atrophy Treatment. International Journal of Molecular Biotechnological Research. 2024; 02(02):-. Available from: https://journals.stmjournals.com/ijmbr/article=2024/view=0
References
document.addEventListener(‘DOMContentLoaded’,function(){frmFrontForm.scrollToID(‘frm_container_ref_114088’);});Edit
1. R. Sakakibara, “Multiple system atrophy,” in Neurourology: Theory and Practice, Springer Netherlands, 2019, pp. 549–562. doi: 10.1007/978-94-017-7509-0_65. 2. M. Herrera-Vaquero et al., “Signs of early cellular dysfunction in multiple system atrophy,” Neuropathol Appl Neurobiol, vol. 47, no. 2, pp. 268–282, Feb. 2021, doi: 10.1111/nan.12661. 3. D. W. Dickson et al., “Widespread alterations of α-synuclein in multiple system atrophy,” American Journal of Pathology, vol. 155, no. 4, pp. 1241–1251, 1999, doi: 10.1016/S0002-9440(10)65226-1. 4. N. Campese, A. Fanciulli, N. Stefanova, J. Haybaeck, S. Kiechl, and G. K. Wenning, “Neuropathology of multiple system atrophy: Kurt Jellinger`s legacy,” Journal of Neural Transmission, vol. 128, no. 10. Springer, pp. 1481–1494, Oct. 01, 2021. doi: 10.1007/s00702-021-02383-3. 5. H. X. J. W. Sigal Kaplan, “Estimating the prevalence and incidence of multiple system atrophy in the USA: Insights from a national claims database,” Parkinsonism Relat Disord, vol. Volume 117, 2023. 6. K. A. Jellinger and K. Jellinger, “Recent advances in multiple system atrophy Keywords Multiple system atrophy Α-synuclein Glial/neuronal inclusions Oligodendrogliopathy Neurodegeneration Etiopathogenesis Fluid biomarker Treatment options,” 2016. [Online]. Available: www.jneurology.comNeuromedicine 7. E. Fitzgerald, S. Murphy, and H. A. Martinson, “Alpha-synuclein pathology and the role of the microbiota in Parkinson’s disease,” Frontiers in Neuroscience, vol. 13, no. APR. Frontiers Media S.A., 2019. doi: 10.3389/fnins.2019.00369. 8. E. Srinivasan et al., “Alpha-Synuclein Aggregation in Parkinson’s Disease,” Frontiers in Medicine, vol. 8. Frontiers Media S.A., Oct. 18, 2021. doi: 10.3389/fmed.2021.736978. 9. N. Stefanova, P. Bücke, S. Duerr, and G. K. Wenning, “Multiple system atrophy: an update,” The Lancet Neurology, vol. 8, no. 12. pp. 1172–1178, Dec. 2009. doi: 10.1016/S1474-4422(09)70288-1. 10. G. Monzio Compagnoni and A. Di Fonzo, “Understanding the pathogenesis of multiple system atrophy: state of the art and future perspectives,” Acta neuropathologica communications, vol. 7, no. 1. NLM (Medline), p. 113, Jul. 12, 2019. doi: 10.1186/s40478-019-0730-6. 11. H. J. Lee, D. Ricarte, D. Ortiz, and S. J. Lee, “Models of multiple system atrophy,” Experimental and Molecular Medicine, vol. 51, no. 11. Nature Publishing Group, Nov. 01, 2019. doi: 10.1038/s12276-019-0346-8. 12. S. Koga and D. W. Dickson, “Recent advances in neuropathology, biomarkers and therapeutic approach of multiple system atrophy,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 89, no. 2. BMJ Publishing Group, pp. 175–184, Feb. 01, 2018. doi: 10.1136/jnnp-2017-315813. 13. I. Yazawa et al., “Mouse model of multiple system atrophy α-synuclein expression in oligodendrocytes causes glial and neuronal degeneration,” Neuron, vol. 45, no. 6, pp. 847–859, Mar. 2005, doi: 10.1016/j.neuron.2005.01.032. 14. A. A. Farooqui, T. Farooqui, A. Madan, J. H. J. Ong, and W. Y. Ong, “Ayurvedic Medicine for the Treatment of Dementia: Mechanistic Aspects,” Evidence-based Complementary and Alternative Medicine, vol. 2018. Hindawi Limited, 2018. doi: 10.1155/2018/2481076. 15. S. Kumar, G. J. Dobos, and T. Rampp, “The Significance of Ayurvedic Medicinal Plants,” Journal of Evidence-Based Complementary and Alternative Medicine, vol. 22, no. 3. SAGE Publications Ltd, pp. 494–501, Jul. 01, 2017. doi: 10.1177/2156587216671392. 16. S. Chavan Scholar, “Kesari Mahratta Trust-(Copyright-2022) Volume-I, Issue-I,” 2022, [Online]. Available: www.mahratta.org,[email protected] 17. S. S. P. Caetano et al., “Characterization and bioactive compounds of organic Bordeaux grape seed oil and flours (Vitis labrusca L.),” Research, Society and Development, vol. 11, no. 14, p. e55111435888, Oct. 2022, doi: 10.33448/rsd-v11i14.35888. 18. J. Garavaglia, M. M. Markoski, A. Oliveira, and A. Marcadenti, “Grape seed oil compounds: Biological and chemical actions for health,” Nutrition and Metabolic Insights, vol. 9. Libertas Academica Ltd., pp. 59–64, Aug. 16, 2016. doi: 10.4137/NMI.S32910. 19. M. Gupta, S. Dey, D. Marbaniang, P. Pal, S. Ray, and B. Mazumder, “Grape seed extract: having a potential health benefits,” Journal of Food Science and Technology, vol. 57, no. 4. Springer, pp. 1205–1215, Apr. 01, 2020. doi: 10.1007/s13197-019-04113-w. 20. G. Hey et al., “Therapies for Parkinson’s disease and the gut microbiome: evidence for bidirectional connection,” Frontiers in Aging Neuroscience, vol. 15. Frontiers Media S.A., 2023. doi: 10.3389/fnagi.2023.1151850. 21. S. J. Fandy, “GRAPE SEED EXTRACT’S NEUROPROTECTIVE EFFECT AND PARKINSON’S DISEASE: A SYSTEMATIC REVIEW,” MNJ (Malang Neurology Journal), vol. 9, no. 1, pp. 44–51, Dec. 2022, doi: 10.21776/ub.mnj.2023.009.01.9. 22. B. F. Polegato et al., “Role of Thiamin in Health and Disease,” Nutrition in Clinical Practice, vol. 34, no. 4. John Wiley and Sons Inc., pp. 558–564, Aug. 01, 2019. doi: 10.1002/ncp.10234. 23. A. Costantini et al., “Long-term treatment with high-dose thiamine in Parkinson disease: An open-label pilot study,” Journal of Alternative and Complementary Medicine, vol. 21, no. 12, pp. 740–747, Dec. 2015, doi: 10.1089/acm.2014.0353. 24. K. V. Q. Luong and L. T. H. Nguyễn, “The beneficial role of thiamine in parkinson disease,” CNS Neuroscience and Therapeutics, vol. 19, no. 7. pp. 461–468, Jul. 2013. doi: 10.1111/cns.12078. 25. S. N. Rai, P. Singh, H. W. M. Steinbusch, E. Vamanu, G. Ashraf, and M. P. Singh, “The role of vitamins in neurodegenerative disease: An update,” Biomedicines, vol. 9, no. 10. MDPI, Oct. 01, 2021. doi: 10.3390/biomedicines9101284. 26. K. Mohanraj et al., “IMPPAT: A curated database of Indian Medicinal Plants, Phytochemistry and Therapeutics,” Sci Rep, vol. 8, no. 1, Dec. 2018, doi: 10.1038/s41598-018-22631-z. 27. S. Kim et al., “PubChem substance and compound databases,” Nucleic Acids Res, vol. 44, no. D1, pp. D1202–D1213, 2016, doi: 10.1093/nar/gkv951. 28. P. Tripathi, S. Ghosh, and S. Nath Talapatra, “Bioavailability prediction of phytochemicals present in Calotropis procera (Aiton) R. Br. by using Swiss-ADME tool,” World Sci News, vol. 131, pp. 147–163, 2019, [Online]. Available: www.worldscientificnews.com 29. V. Ivanović, M. Rančić, B. Arsić, and A. Pavlović, “Lipinski’s rule of five, famous extensions and famous exceptions.” 30. S. Prasanna and R. Doerksen, “Topological Polar Surface Area: A Useful Descriptor in 2D-QSAR,” Curr Med Chem, vol. 16, no. 1, pp. 21–41, Dec. 2008, doi: 10.2174/092986709787002817. 31. B. Chandrasekaran, S. N. Abed, O. Al-Attraqchi, K. Kuche, and R. K. Tekade, “Computer-Aided Prediction of Pharmacokinetic (ADMET) Properties,” in Dosage Form Design Parameters, vol. 2, Elsevier, 2018, pp. 731–755. doi: 10.1016/B978-0-12-814421-3.00021-X. 32. N. Rani, A. Kumar Jha, and N. Khare, “Molecular Docking Study of Dihydrohelenalin against DNMT1 to Treat Oral Cancer,” International Journal of Research and Analytical Reviews, vol. 7, no. 3, 2020, [Online]. Available: www.ijrar.org 33. S. A. Hollingsworth and P. A. Karplus, “A fresh look at the Ramachandran plot and the occurrence of standard structures in proteins,” Biomolecular Concepts, vol. 1, no. 3–4. De Gruyter Mouton, pp. 271–283, Oct. 01, 2010. doi: 10.1515/bmc.2010.022. 34. P. Kumar and A. Arya, “Ramachandran plot-A simplified approach.” [Online]. Available: https://www.researchgate.net/publication/330158666 35. R. A. Laskowski, “Enhancing the functional annotation of PDB structures in PDBsum using key figures extracted from the literature,” Bioinformatics, vol. 23, no. 14, pp. 1824–1827, Jul. 2007, doi: 10.1093/bioinformatics/btm085. 36. R. P. Pawar and S. H. Rohane, “Role of Autodock vina in PyRx Molecular Docking,” Asian J. Research Chem, vol. 14, no. 2, doi: 10.5958/0974-4150.2021.00024.9. 37. S. Agarwal and R. Mehrotra, “An overview of Molecular Docking,” JSM Chem, vol. 4, no.2,p.1024,2016,[Online].Available: https://www.researchgate.net/publication/303897563 38. [38] M. Tahir, M. Baharuddin, and A. Najib, “In silico screening of brotowali (Tinospora crispa L.) chemical compounds as α-glucosidase inhibitor using the pyrx program,” in AIP Conference Proceedings, American Institute of Physics Inc., May 2023. doi: 10.1063/5.0123693. 39. [39] G. Monzio Compagnoni and A. Di Fonzo, “Understanding the pathogenesis of multiple system atrophy: state of the art and future perspectives,” Acta neuropathologica communications, vol. 7, no. 1. NLM (Medline), p. 113, Jul. 12, 2019. doi: 10.1186/s40478-019-0730-6. 40. D. Valdinocci, R. A. W. Radford, M. Goulding, J. Hayashi, R. S. Chung, and D. L. Pountney, “Extracellular interactions of Alpha-synuclein in multiple system atrophy,” International Journal of Molecular Sciences, vol. 19, no. 12. MDPI AG, 2018. doi: 10.3390/ijms19124129. 41. B. F. Polegato et al., “Role of Thiamin in Health and Disease,” Nutrition in Clinical Practice, vol. 34, no. 4. John Wiley and Sons Inc., pp. 558–564, Aug. 01, 2019. doi: 10.1002/ncp.10234.
| Volume | 02 |
| Issue | 02 |
| Received | 28/10/2024 |
| Accepted | 05/11/2024 |
| Published | 18/11/2024 |